Zai Lab posts Q3 2026 revenue of $108.2M, closes $250M private placement, advances zoci toward 2027 filings

On November 5, 2026, Zai Lab reported Q3 2026 results: total revenue of $108.2M (down from $116.1M a year earlier) and a net loss of $46.1M. The company closed a roughly $250M ADS private placement on October 27 and said that, following FDA feedback, it will pursue accelerated approval for zocilurtatug pelitecan (zoci) in 2L+ extrapulmonary neuroendocrine carcinomas. It is also advancing zoci plus atezolizumab into a global Phase 3 study in first-line extensive-stage small cell lung cancer.

05 Nov 2026 · Zai Lab Ltd ZLAB · Company news

Company's press release (SEC filing): Zai Lab Ltd ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More FinancingAll →

Financing

Zai Lab posts Q3 2026 revenue of $108.2M, closes $250M private placement, advances zoci toward 2027 filings

IM Cannabis reports C$13.9M nine-month net loss as revenue slides to C$9.0M

Femasys Q3 2026: $30M private placement closed; U.S. sales flat, total sales fall 44.5% to $404,597

Mingteng International, an automotive mold maker, prices $2.00/share registered direct offering with pre-funded warrants

Organigram to acquire Aurora Cannabis for about C$561M, backed by BAT private placement and ATB credit facilities

Windward Bio prices Nasdaq IPO of 10.3 million shares at $17, targeting $225 million in gross proceeds

Lichen International prices $3.5M registered direct offering of units with warrants on Nasdaq